{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:28:10Z","timestamp":1790962090647,"version":"4.1.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"\n Importance<\/jats:title>\n The Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation (ARTESiA) randomized clinical trial showed that in patients with subclinical atrial fibrillation (SCAF) apixaban, compared with aspirin, reduced stroke\/systemic embolism but increased major bleeding.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To characterize major bleeding events (site and severity) and identify factors associated with major bleeding.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This was a prespecified subanalysis of the ARTESiA population who received treatment. This was an international, double-blind, double-dummy randomized clinical trial. Included were patients with 1 or more episodes of SCAF lasting 6 minutes to 24 hours with stroke risk factors (CHA\n 2<\/jats:sub>\n DS\n 2<\/jats:sub>\n -VASc score \u22653) or prior stroke without other risk factors. Study data were analyzed from August to November 2024.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Apixaban, 5 mg, twice daily (2.5 mg twice daily when indicated) or aspirin, 81 mg, once daily.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Major bleeding adjudicated by a blinded committee according to International Society on Thrombosis and Hemostasis criteria.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 3961 patients (mean [SD] age, 76.8 [7.6] years; 2535 male [64%]) were included in this analysis. After a mean (SD) follow-up of 3.5 (1.8) years, 1 or more major bleeding episodes occurred in 133 patients, 86 of 1989 taking apixaban and 47 of 1972 taking aspirin (1.71 vs 0.94 per 100-patient-years; hazard ratio [HR], 1.80; 95% CI, 1.26-2.57). The rates of intracranial (0.33 vs 0.40 per 100 patient-years; HR, 0.82; 95% CI, 0.43-1.57) and fatal (0.10% vs 0.16% per 100 patient-years; HR, 0.63; 95% CI, 0.20-1.91) bleeding were similar in the apixaban and aspirin groups, whereas the rate of gastrointestinal bleeding was higher in the apixaban group (0.89% vs 0.40% per 100 patient-years; HR, 2.23; 95% CI, 1.32-3.78). Among 133 index major bleeding events, those that occurred with apixaban were less likely to occur at critical sites (27.9% [24 of 86] vs 46.8% [22 of 47];\n P<\/jats:italic>\n \u2009=\u2009.03) including intracranial (18.6% [16 of 86] vs 42.6% [20 of 47];\n P<\/jats:italic>\n \u2009=\u2009.003). Most major bleeding events were nonemergencies characterized by decreased hemoglobin greater than or equal to 2 g\/dL. Factors associated with major bleeding included nonsteroidal anti-inflammatory drug (NSAID) use (HR, 10.25; 95% CI, 6.57-15.99), cancer (HR, 2.87; 95% CI, 1.49-5.53), randomization to apixaban (HR, 1.84; 95% CI, 1.29-2.63), and age (HR, 1.47; 95% CI, 1.28-1.67, per 5-year increase).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this subanalysis of the ARTESiA randomized clinical trial found that although the rate of major gastrointestinal bleeding was higher in patients with SCAF who were treated with apixaban vs aspirin, rates of fatal and intracranial bleeding were not different. Most major bleeding events were nonemergencies characterized by a decrease in hemoglobin level greater than or equal to 2 g\/dL. NSAID use, cancer, randomization to apixaban, and increasing age were associated with an increased risk of major bleeding.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT01938248<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.4151","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T16:00:43Z","timestamp":1762963243000},"page":"1305","source":"Crossref","is-referenced-by-count":5,"title":["Major Bleeding With Apixaban vs Aspirin"],"prefix":"10.1001","volume":"10","author":[{"given":"Deborah M.","family":"Siegal","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sticherling","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S.","family":"Healey","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene S.","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital of Southern Jutland, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratika","family":"Parkash","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vanassche","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Conen","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Cosedis","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Wojdyla","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia W.","family":"Erath","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Goethe University Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Rivard","sequence":"additional","affiliation":[{"name":"Department of Medicine, and Research Centre, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Kutyifa","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Wright","sequence":"additional","affiliation":[{"name":"Liverpool Heart and Chest Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"hoi250063r1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke.","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi250063r2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"9","key":"hoi250063r3","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/europace\/eux163","article-title":"Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE).","volume":"19","author":"Gorenek","year":"2017","journal-title":"Europace"},{"issue":"38","key":"hoi250063r4","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"11","key":"hoi250063r5","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.cjca.2018.08.026","article-title":"2018 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation.","volume":"34","author":"Andrade","year":"2018","journal-title":"Can J Cardiol"},{"issue":"2","key":"hoi250063r6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation.","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"hoi250063r7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials.","volume":"149","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"hoi250063r8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"10","key":"hoi250063r9","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1160\/TH16-12-0946","article-title":"Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists.","volume":"117","author":"Bleker","year":"2017","journal-title":"Thromb Haemost"},{"issue":"7","key":"hoi250063r10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism.","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi250063r11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1160\/TH15-11-0892","article-title":"Clinical impact and course of major bleeding with edoxaban vs vitamin K antagonists.","volume":"116","author":"Brekelmans","year":"2016","journal-title":"Thromb Haemost"},{"issue":"9","key":"hoi250063r12","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/jth.13051","article-title":"Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.","volume":"13","author":"Eerenberg","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"9","key":"hoi250063r13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation.","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi250063r14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/ageing\/afv156","article-title":"Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.","volume":"45","author":"Ng","year":"2016","journal-title":"Age Ageing"},{"issue":"28","key":"hoi250063r15","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"issue":"5","key":"hoi250063r16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"hoi250063r17","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes.","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi250063r18","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1182\/bloodadvances.2024014219","article-title":"American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary.","volume":"9","author":"Siegal","year":"2025","journal-title":"Blood Adv"},{"key":"hoi250063r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111639","article-title":"Defining decision thresholds for judgments on health benefits and harms using the grading of recommendations assessment, development, and evaluation (GRADE) evidence to decision (EtD) frameworks: a randomized methodological study (GRADE-THRESHOLD).","volume":"179","author":"Morgano","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"hoi250063r20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006703","article-title":"Impact of spontaneous extracranial bleeding events on health state utility in patients with atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial.","volume":"6","author":"Wang","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"hoi250063r21","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jtha.2025.02.013","article-title":"Functional disability after clinically significant extracranial bleeding: a secondary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial.","volume":"23","author":"Li","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"4","key":"hoi250063r22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jacc.2024.05.002","article-title":"Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA.","volume":"84","author":"Lopes","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hoi250063r23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S1474-4422(24)00475-7","article-title":"Apixaban vs aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial.","volume":"24","author":"Shoamanesh","year":"2025","journal-title":"Lancet Neurol"},{"issue":"7323","key":"hoi250063r24","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/bmj.323.7323.1218","article-title":"Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.","volume":"323","author":"Devereaux","year":"2001","journal-title":"BMJ"},{"issue":"3","key":"hoi250063r25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1160\/TH13-05-0424","article-title":"Evaluation of patients\u2019 attitudes toward stroke prevention and bleeding risk in atrial fibrillation.","volume":"111","author":"Lahaye","year":"2014","journal-title":"Thromb Haemost"},{"issue":"3","key":"hoi250063r26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jacc.2018.04.063","article-title":"Concomitant oral anticoagulant and nonsteroidal anti-inflammatory drug therapy in patients with atrial fibrillation.","volume":"72","author":"Kent","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi250063r27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.119.041296","article-title":"Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE Trial.","volume":"141","author":"Dalgaard","year":"2020","journal-title":"Circulation"},{"issue":"12","key":"hoi250063r28","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial.","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"issue":"2","key":"hoi250063r29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs warfarin in patients with nonvalvular atrial fibrillation and a history of cancer: observations from ROCKET AF.","volume":"5","author":"Chen","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2841075\/jamacardiology_siegal_2025_oi_250063_1765206608.81213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:00:36Z","timestamp":1765382436000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2841075"}},"subtitle":["A Subanalysis of the ARTESiA Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.4151","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}